Enterprise Value
1.315B
Cash
431.1M
Avg Qtr Burn
-36.23M
Short % of Float
13.24%
Insider Ownership
2.40%
Institutional Own.
94.28%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SGR-2921 (CDC7 inhibitor) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1 Data readout | |
SGR-1505 (MALT1 inhibitor) Details Cancer, B-cell malignancies | Phase 1 Data readout | |
SGR-3515 (Wee1/Myt1 inhibitor) Details Solid tumor/s | Phase 1 Initiation |